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Inflammation is defined as a physiological response initiated by a variety of conditions
that cause insult to the body, such as infection and tissue injury. Inflammation is trig-
gered by specialized receptors in the innate immune system, which recognize microbial
components known as pathogen-associated molecular patterns or endogenous signals
produced by damaged cells (damage-associated molecular patterns). IL-33 is a cytokine
that is released predominantly at the epithelial barrier when it is exposed to pathogens,
allergens, or injury-inducing stimuli. IL-33 target cells are various, ranging from hematopoi-
etic stem and progenitor cells (HSPCs) and essentially all types of their progeny to many
non-hematopoietic cells. The pleiotropic actions of IL-33 suggest that IL-33 is involved in
every phase of the inflammatory process. In this review, we discuss recent advances in
the understanding of how IL-33 orchestrates inflammatory responses by regulating HSPCs
and innate immune cells.
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INTRODUCTION
Epithelial cells are exposed to external environments on one side,
and segregated from the other tissue’s components by the base-
ment membrane on the other side. When they receive extrinsic
and intrinsic insults, they release or produce soluble factors that
act on stromal cells and immune cells. Damaged cells passively
release damage-associated molecular patterns (DAMPs) from the
disrupted plasma membrane. DAMPs stimulate adjacent epithelial
cells or myeloid cells to secrete inflammatory mediators. Intracel-
lular stores of IL-33 are released from epithelial cells upon infection
or injury (Kurowska-Stolarska et al., 2009; Pastorelli et al., 2010;
Wills-Karp et al., 2012). This review focuses on how IL-33 regulates
inflammation by targeting hematopoietic stem and progenitor
cells (HSPCs) and immune cells.
EXPRESSION AND SECRETION OF IL-33
IL-33 was initially found to be highly expressed in the nuclei of
high endothelial venules (Baekkevold et al., 2003). Later studies
further identified IL-33 as a chromatin-associated nuclear factor
inhibiting gene transcription (Carriere et al., 2007; Roussel et al.,
2008; Ali et al., 2011). A recent study showed that IL-33 is also
found in the cytoplasm (Kakkar et al., 2012). Having been shown
to bind to ST2, which is selectively expressed on Th2 cells (Xu
et al., 1998; Schmitz et al., 2005), IL-33 was once recognized as a
Th2 cytokine. However, its functions far exceed Th2 immunity, as
reflected by its broad expression in organs and cell types (reviewed
in Mirchandani et al., 2012). IL-33-expressing cells include the
stromal and parenchymal cells of organs and immune cells such
as macrophages, dendritic cells, mast cells, epithelial cells, smooth
muscle cells, fibroblast cells, myofibroblasts, endothelial cells, glial
cells, osteoblasts, and adipocytes. Various stimuli are known to
induce or upregulate IL-33 expression. In mast cells, IL-33 expres-
sion is inducible by the FcεRI signaling pathway that leads to
activation of the nuclear factor of activated T cells (NFAT) via
Ca2+ (Hsu and Bryce, 2012). In dendritic cells, macrophages and
fibroblasts, IL-33 mRNA expression can also be induced by TLR
stimulation (Talabot-Ayer et al., 2012).
The process by which IL-33 is released from the nucleus is still
a matter of debate. Like the other two cytokines in the IL-1 fam-
ily, IL-1β and IL-18, IL-33 was once thought to be processed by
caspase-1, a component of inflammasomes, to become an active
form (Schmitz et al., 2005). Yet recent results have demonstrated
that full-length IL-33 has full biological activity, and that IL-33
cleavage by caspases results in inactivation of IL-33 (Cayrol and
Girard, 2009; Lüthi et al., 2009; Talabot-Ayer et al., 2009; Ali et al.,
2010). Although controversy remains as to which type of caspase
processes full-length IL-33, it seems that IL-33 is preferentially
released from cells during necrosis, and cleaved into inactive forms
inside cells during apoptosis (Lüthi et al., 2009). The pattern of
IL-33 release is characteristic of endogenous danger signals or
alarmins such as the high-mobility group protein B-1 (HMGB-1)
and IL-1α (Lamkanifi and Dixit, 2009). The observation that IL-33
is highly expressed in endothelial and epithelial cells which con-
front environmental threats and are vulnerable to tissue damage
also indicates that IL-33 fulfills the requirements of DAMPs, which
alert and drive the immune system to manage tissue injury and
www.frontiersin.org May 2013 | Volume 4 | Article 104 | 1
Le et al. IL-33 and hematopoietic cells
infection by inducing inflammation (Moussion and Girard, 2008).
Indeed, the IL-33 released by endothelial cells of renal microvas-
culature in response to a necrosis-inducing dose of cisplatin, has a
crucial role in exacerbating acute kidney injury (Akcay et al., 2011).
However, full-length IL-33 released during inflammation can be
proteolytically matured into more bioactive forms by neutrophil
elastase and cathepsin G (Lefrancais et al., 2012). Cleaved forms of
IL-33 with a greater bioactivity are genuine cytokines that bind to
ST2, whilst it has been suggested that full-length IL-33 functions
as a DAMP in a ST2-independent way (Luzina et al., 2012). In
sum, it seems that IL-33 is passively released from the epithelial
barrier which undergo tissue injury, necrosis, and infection and
participates in inflammatory processes after taking a more mature
form in the extracellular environment with help from neutrophils.
It should be noted that chyamase mast cell protease 4, a degran-
ulation product of mast cells, degrades IL-33 in the extracellular
matrix and thereby reduce inflammation progression (Waern et al.,
2012).
High levels of serum IL-33 are observed in various inflamma-
tory diseases, suggesting that a mechanism exists for the active
secretion of IL-33 (Mirchandani et al., 2012). TLRs are typical
triggers for the secretion of IL-33. One remarkable in vivo exam-
ple is provided by influenza virus, which promotes IL-33 secretion
from alveolar macrophages by stimulating TLR7 signaling (Chang
et al., 2011). Indeed, a recent result has shown that mechanical
strain in fibroblasts can lead to production of IL-33 without evi-
dence of necrosis which, along with the evidence that IL-33 can
traffic between membrane bound-vesicles and the nucleus, sug-
gests that secretion of IL-33 by a classical pathway may be involved
(Kakkar et al., 2012). Identifying the signaling pathways leading to
IL-33 secretion is an interesting task that has yet to be completed.
TARGETS OF IL-33
Virtually all types of immune cells and numerous types of non-
immune cells respond to IL-33 via its receptor, the ST2-IL-1
receptor accessory protein complex (Mirchandani et al., 2012).
The expression pattern of IL-33 receptor indicates that it regu-
lates a complex cellular network consisting of immune cells and
non-immune cells.
LYMPHOCYTES
Lymphocyte subsets capable of responding to IL-33 include Th2
cells, a small population of IL-4-independent atypical Th2 cells
(Xu et al., 1998; Kurowska-Stolarska et al., 2008), activated CD8+
T cells (Yang et al., 2011; Bonilla et al., 2012), B-1 B cells (Komai-
Koma et al., 2011), and NKT cells (Smithgall et al., 2008; Bourgeois
et al., 2009; Chen et al., 2012; Kim et al., 2012a). IL-33 stimulates
conventional Th2 cells to release IL-4, IL-5, and IL-13 and IL-33-
driven Th2 cells profoundly inhibit atherosclerosis (Miller et al.,
2008). However, in combination with STAT5-activating cytokines
(IL-2, IL-7, and TSLP), IL-33 induces the production of IL-5 and
IL-13 but not IL-4 by effector Th2 cells in a TCR-independent
fashion (Guo et al., 2009). Even though the significance of this
cytokine-induced cytokine production in Th2 cells is unknown
(Guo et al., 2012), atypical Th2 and B-1 B cells show the same
pattern of cytokine production in response to IL-33 (Kurowska-
Stolarska et al., 2008; Komai-Koma et al., 2011). IL-33 polarizes
IL-4−/− CD4+ T cells into IL-5- and IL-13-producing Th2 cells in
the presence of antigen (Kurowska-Stolarska et al., 2008), suggest-
ing that IL-33 may be responsible for the IL-4-independent com-
mitment of Th2 cells. The IL-33-mediated by B-1 cell functions
depend largely upon IL-5 that was thought to be produced B-1 cell
themselves and other immune cells (Komai-Koma et al., 2011).
Similar activity is observed of IL-33 in NKT cells, whose secretion
of IFN-γ is induced by IL-33 either alone or in combination with
TCR stimulation or IL-12 (Smithgall et al., 2008; Bourgeois et al.,
2009). In an airway hypersensitivity model, antigen-stimulated
NKT cells induced production of IL-33 by alveolar macrophages,
CD11c+ dendritic cells and type II pneumocytes, which in turn
activated NKT cells to produce IL-13 (Kim et al., 2012a).
INNATE LYMPHOID CELLS
Among innate lymphoid cells, NK cells and type 2 innate lymphoid
cells (ILC2s) are known to respond to IL-33. NK cells produce
IFN-γ as a result of stimulation with IL-33 and IL-12 (Smithgall
et al., 2008; Bourgeois et al., 2009). ILC2s are a subset of lymphoid
cells only recently identified by many laboratories and referred to
by various names. These cells are heterogeneous, but have certain
properties in common. They express similar cell surface molecules
and secrete IL-5 and IL-13 (Moro et al., 2010; Neill et al., 2010;
Price et al., 2010). They also lack hematopoietic lineage mark-
ers and express hematopoietic stem cell markers such as Sca-1
and c-Kit, and cytokine receptors such as CD25 (IL-2Rα), CD125
(IL7Rα), IL-17RB (IL-25 receptor), and ST2. All ILC2s respond
to epithelial cytokines IL-25, TSLP, and IL-33 and play a pivotal
role in anti-helminth responses and airway hypersensitivity in an
adaptive immunity-independent fashion.
All types of ILCs are differentiated from Id2-expressing com-
mon lymphoid progenitors (CLPs) (Yokota et al., 1999; Moro
et al., 2010; Hoyler et al., 2012). The specification of ILC2s is
determined by the Th2 transcription factor GATA3 and a retinoic
acid-related orphan nuclear receptor family α (RORα) (Halim
et al., 2012; Wong et al., 2012). As ILC2s are absent in IL-2 receptor
γ chain-deficient mice, IL-2 or IL-7 seems to be required for their
maintenance (Moro et al., 2010; Neill et al., 2010). In addition,
IL-2 or IL-7 has a synergistic action on both the proliferation of
purified ILC2s and their cytokine production with IL-33. How-
ever, it is not known yet how in vivo administration with IL-25 or
IL-33 leads to an enormous increase in ILC2s and the production
of high levels of IL-4, IL-5, and IL-13 (Schmitz et al., 2005; Moro
et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2011).
MYELOID CELLS
ST2 is expressed in granulocytes and other myeloid cells which
play a role in Th2 immunity. IL-33 treatment induces eosinophilia
in mice (Pecaric-Petkovic et al., 2009; Chow et al., 2010; Kim
et al., 2010; Stolarski et al., 2010). This is thought to be due
to IL-5 production by several types of cells (Kim et al., 2010).
The main IL-5 source after IL-33 treatment was recently found
to be ILC2-like non-T cells (Ikutani et al., 2012). However, the
direct effects of IL-33 on eosinophils are evident. For example,
IL-33 induces eosinophil differentiation from bone marrow prog-
enitors through stimulation of IL-5 production in an autocrine
fashion (Stolarski et al., 2010). Alone or in cooperation with other
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cytokines such as GM-CSF, IL-3, or IL-5, IL-33 stimulates the acti-
vation of eosinophils to secrete various cytokines and chemokines,
upregulates cell adhesion molecules, promotes degranulation, and
increases cell survival (Cherry et al., 2008; Suzukawa et al., 2008a;
Pecaric-Petkovic et al., 2009; Chow et al., 2010; Stolarski et al.,
2010).
ST2 expression is inducible in basophils by IL-3 (Pecaric-
Petkovic et al., 2009). Basophils secrete various cytokines and
chemokines in response to IL-3 plus IL-33 or an IgE-antigen com-
plex plus IL-33. The types of cytokines and chemokines produced
by basophils are similar to those released from ILC2s (i.e., IL-4,
IL-5, IL-6, IL-8, IL-9, IL-13, and GM-CSF) (Smithgall et al., 2008;
Pecaric-Petkovic et al., 2009; Blom et al., 2011). It seems that the
action of IL-33 on basophils is to prime them to respond through
main receptors such as the IL-3, IgE, or chemokine receptors
(Suzukawa et al., 2008b). The promotion of basophil differen-
tiation by IL-33 depends upon growth factors such as GM-CSF
which is produced by bone marrow cells after L-33 stimulation
(Schneider et al., 2009). However, some researchers have reported
that IL-33 directly upregulates CD11b, IL-4, and IL-6 in basophils
(Suzukawa et al., 2008b; Schneider et al., 2009).
IL-33 has significant effects on the biological activities of mast
cells which play a major role in Th2 immunity and acute inflam-
mation (reviewed by Lunderius-Andersson et al., 2012). Alone
or in combination with SCF, IL-33 promotes mast cell differen-
tiation, maturation, and survival (Allakhverdi et al., 2007; Iikura
et al., 2007; Kaieda et al., 2010). There are various mechanisms for
the action of IL-33 on mast cells. First, IL-33 may activate mast
cells to release various cytokines, chemokines, and lipid mediators
without degranulation (Allakhverdi et al., 2007; Ho et al., 2007;
Moulin et al., 2007; Silver et al., 2010). Second, IL-33 may enhance
the release of these cytokines, chemokines, and lipid mediators
from mast cells in a degranulation-dependent or -independent
fashion after stimulation with FcεRI or other receptors such as the
substance P receptor (Theoharides et al., 2010).
Evidence is accumulating for the various modulatory effects
of IL-33 on neutrophils. IL-33 enhances the migratory ability of
neutrophils by preventing the downregulation of CXCR2 (Alves-
Filho et al., 2010). This occurs because IL-33 inhibits G protein-
coupled receptor kinase-1 (GRK-1) downregulation which is
induced by TLR signaling during infection by bacteria or fungi
(Alves-Filho et al., 2009, 2010; Le et al., 2012). IL-33 also induces
the recruitment of neutrophils to sites of infection through the
release of chemokines, such as CXCL1, CXCL2, and CCL3, from
macrophages (Verri et al., 2010; Le et al., 2012). After exposure
to Candida albicans, IL-33-primed neutrophils rapidly increase
their cell surface complement receptor 3 (CR3: CD11b/CD18)
in a TLRs- and Dectin-1-dependent manner, and exhibit higher
phagocytic and fungicidal activity (Le et al., 2012). In vivo, the
biological activity brought about by IL-33 is critical to bacterial
and fungal clearance (Alves-Filho et al., 2010; Le et al., 2012).
IL-33 drives macrophages to differentiate into alternatively acti-
vated M2 macrophages (Kurowska-Stolarska et al., 2009). IL-13
seems to be required for the IL-33-mediated differentiation of
macrophages toward an M2 type, because it induces ST2 expres-
sion on the cell surface. Together the two cytokines have a syn-
ergistic effect on M2 differentiation (Kurowska-Stolarska et al.,
2009). M2 macrophages generated by IL-33 in vivo show func-
tional diversity. For example, IL-33-stimulated M2 macrophages
play a critical role in the recruitment of leukocytes by producing
chemokines (Kurowska-Stolarska et al., 2009), whereas IL-33-
polarized M2 macrophages significantly decreased keratitis caused
by Pseudomonas aeruginosa (Hazlett et al., 2010). The mechanism
behind the association of M2 polarization with bacterial or fungal
clearance is unknown (Hazlett et al., 2010; Nelson et al., 2011). As
IL-33 seems to have little influence on the phagocytic activity of
macrophages (Le et al., 2012), its beneficial effects on the host may
be twofold: inhibiting hyperresponses to pathogens through M2
polarization, and enhancing the clearance of pathogens by neu-
trophils. However, responses to IL-33 are likely to vary according
to pathogen type (Espinassous et al., 2009).
IL-33 regulates dendritic cells in either a positive or a negative
fashion. Cultured bone marrow-derived dendritic cells produce
proinflammatory cytokines and upregulate cell surface molecules
in response to IL-33. IL-33-primed dendritic cells can efficiently
induce allergic airway inflammation (Rank et al., 2009; Besnard
et al., 2011). However, rapamycin-conditioned tolerogenic den-
dritic cells increase ST2 expression in an IL-1β-dependent way
and ST2 promotes resistance to the dendritic cell maturation
induced by TLR2 or CD40 signaling (Turnquist et al., 2008). In
this in vitro model, it is not known whether the inhibition of den-
dritic cell maturation by ST2 depends on IL-33. A recent study has
shown that ST2-deficient dendritic cells are overactivated by the
presence of antigen, which exacerbates experimental autoimmune
encephalomyelitis (Milovanovic et al., 2012).
NON-HEMATOPOIETIC CELLS
IL-33 can function in an autocrine manner in endothelial and
epithelial cells, two cell types that produce a large amount of
IL-33. IL-33 promotes angiogenesis by increasing endothelial cell
proliferation and migration, and induces vascular leakage (Choi
et al., 2009). Endothelial cells also secrete inflammatory media-
tors in response to IL-33 (Yagami et al., 2010), as seen in epithelial
cells (Yagami et al., 2010; Fujita et al., 2012). During helminth
infection, intestinal epithelial cells induce the production of IL-
25, IL-33, and TSLP. This process of induction requires mast cells
(Hepworth et al., 2012). IL-25 replaces mast cells in cases of anti-
helminth responses. The target cells for IL-25, and presumably
the other two cytokines, are the mast cell progenitors that pro-
duce IL-5 and IL-9 in response to IL-2 and IL-33 (Hepworth et al.,
2012). In ConA-induced hepatitis, NKT cells activate hepatocytes
via TRAIL receptors to produce IL-33 (Arshad et al., 2011, 2012).
IL-33 in turn has a protective role in hepatitis. Consistent with
this, in vivo treatment with IL-33 has been shown to decrease liver
ischemia-reperfusion injury by preventing the necrosis of hepa-
tocytes with no influence on the production of proinflammatory
mediators by Kupffer cells or hepatocytes (Sakai et al., 2012).
HEMATOPOIETIC STEM AND PROGENITOR CELLS
Recent studies have demonstrated that HSPCs participate in
inflammation. Although few reports have identified IL-33-
mediated biological activity in HSPCs, IL-33 seems to control
inflammation by modulating HSPCs either directly or indirectly.
ST2 is expressed on hematopoietic stem cells and various subsets
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FIGURE 1 | Expression of ST2 on HSPCs. Lineage marker-negative cells
were enriched from BM suspension before staining with antibodies to
hematopoietic subsets and ST2. The open histogram depicts staining with
the isotype-matched Ab. LKS+, lin−c-Kit+Sca-1+; LKS−, lin−c-Kit+Sca-1−;
GMP, granulocyte-monocyte progenitor; CMP, common monocyte
progenitor; MEP, megakaryocyte-erythrocyte progenitor; CMP, common
lymphoid progenitor.
of hematopoietic progenitor cells in mice (Figure 1). Helminth
infection has shown to accumulate CD34+Sca-1+ multipotent
progenitor cells in the intestine (Hepworth et al., 2012). These
cells produce IL-5 and IL-9 by stimulation with IL-2 and IL-
33 and differentiate into mast cells in the presence of IL-3 and
SCF. Mast cells are required for the production of IL-25, IL-33,
and TSLP by intestinal epithelial cells following helminth infec-
tion and during subsequent anti-helminth responses (Hepworth
et al., 2012). The unknown mast cell-released factors that stimulate
epithelial cells may have adjuvant signals that stimulate them to
produce sufficiently large quantities of IL-25, IL-33, and TSLP to
mount anti-helminth responses. These cytokines orchestrate anti-
helminth immunity by activating ILC2s, dendritic cells, Th2 cells,
and eosinophils. As IL-25 promotes the accumulation of mul-
tipotent progenitor cells in naïve mice, it seems that there is a
positive-feedback mechanism to amplify Th2 immunity during
helminth infection (Saenz et al., 2011). Similarly, human CD34+
hematopoietic progenitor cells produce IL-5, IL-13, GM-CSF, and
chemokines in response to IL-33 either alone or in combina-
tion with other inflammatory stimuli (Allakhverdi et al., 2009).
Because the sputum of asthmatics may contain either IL-5+ or
IL-13+ hematopoietic progenitor cells, these cells are thought to
contribute to allergic diseases.
Some HSPCs recirculate constantly between the bone marrow
and the periphery for immune surveillance (Massberg et al., 2007).
These cells respond to danger signals and differentiate locally into
resident innate immune cells in organs (Nagai et al., 2006; Mass-
berg et al., 2007). There is extensive experimental evidence that
during the migration and repopulation of HSPCs, chemokine gra-
dients are regulated,along with cell adhesion molecule interactions
in the cellular network of hematopoietic niches. In the case of stress
situations such as inflammation, massive hematopoiesis occurs
in the bone marrow, followed by the large-scale mobilization of
HSPCs and both immature and maturing leukocytes into the cir-
culation. The extramedullary hematopoiesis caused by the mobi-
lization of HSPCs is believed to be important for the clearance of
pathogens and local inflammation. The administration of IL-33,
like that of other inflammatory cytokines (reviewed in Takizawa
et al., 2012) induces an excessive accumulation of myeloid cells in
the periphery (Schmitz et al., 2005). IL-33 increases myelopoiesis
in the bone marrow and the rapid emigration of generated myeloid
cells to the periphery, while inhibiting lymphopoiesis by actively
expelling CLP cells from the bone marrow (Kim et al., unpub-
lished data). In contrast, IL-33 maintains the number of myeloid
progenitor cells in the bone marrow but concomitantly promotes
their massive emigration, suggesting that IL-33 plays a role in the
generation or proliferation of myeloid progenitor cells in the bone
marrow. In the spleens of IL-33-treated mice, IL-33 increases both
lymphopoiesis and myelopoiesis (Kim et al., unpublished data).
During IL-23-mediated colitis, hematopoiesis is dysregulated in
the bone marrow and spleen (Griseri et al., 2012). IFN-γ induces
the accumulation of proliferating HSCs in the bone marrow
and spleen. GM-CSF differentiates these cells into granulocyte-
monocyte progenitor (GMP) cells at the expense of erythroid and
lymphoid progenitors in the spleen. GMPs play a pathogenic role
in colitis. Although the producers of IFN-γ and GM-CSF have yet
to be identified, IL-23-responding ILC1s and ILC17s are candi-
dates. Because IL-33 also induces a skew toward GMP production,
GM-CSF is likely to be involved in this process. Surprisingly, the
main producers of GM-CSF may be HSPCs and ILCs (Allakhverdi
et al., 2009; Moro et al., 2010; Neill et al., 2010; Monticelli et al.,
2011).
It should be noted that because ILC2s and HSPCs share many
cell surface markers and produce similar cytokines such as IL-5,
IL-13, and GM-CSF, technical difficulties arise when attempting
to distinguish between them. Furthermore, as the administration
of IL-25 or IL-33 elicits the expansion of both cell populations
in vivo in lymphoid organs (Moro et al., 2010; Neill et al., 2010;
Saenz et al., 2011), the purification of either subset from IL-25
or IL-33-treated mice cannot exclude the other subset. The only
method available to distinguish between these two subsets is to
compare their capacity to differentiation into mature hematopoi-
etic cells. At the initial phase of inflammation, ILC2s are likely
to respond to IL-33 in organs and as inflammation progresses,
HSPCs may be mobilized to inflamed sites and contribute to
fulminant inflammation by differentiation into granulocytes and
macrophages (models summarized in Figure 2).
REGULATION OF INFLAMMATION BY IL-33
The IL-33-ST2 system seems to be involved in the regulation
of each phase of a generic inflammatory pathway consisting of
inducers, sensors, mediators, and effectors (Medzhitov, 2008).
Endogenous inducers of inflammation are known to be released
from cells or separate tissues after acute tissue injury. As mentioned
previously, IL-33 has been proposed to function as an alarmin or
DAMP, based on its expression in the epithelium and vascular
endothelium whose disruption frequently results in tissue inflam-
mation (Moussion and Girard, 2008; Haraldsen et al., 2009). One
report has shown that IL-33 released by necrotic structural cells
induces inflammation by activating mast cells to produce proin-
flammatory cytokines and leukotrienes (Enoksson et al., 2011).
Mast cells also play an active role in the production of IL-33 by
the helminth-infected intestinal tissue, which promotes their dif-
ferentiation from Lin−CD45− CD34+Sca-1+ progenitors. This
suggests that the mutual regulation of mast cells and intestinal tis-
sue by IL-33 is critical to anti-helminth responses (Hepworth et al.,
2012). If IL-33 is secreted from non-necrotic cells upon exposure
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FIGURE 2 | Models for how IL-33 regulates inflammation
through HSPCs. IL-33 released by injury or infection may stimulate
ILC2s to secrete GM-CSF. On the other hand, vessel cells such as
endothelial cells and smooth muscle cells may produce CCR2
chemokines, in response to IL-33, which promote the emigration of
HSPCs from the bone marrow. GM-CSF in turn may result in
myelopoiesis in the bone marrow and periphery to manage injury
and infection.
to various stimuli (Chang et al., 2011; Kakkar et al., 2012), it should
be classified as an inflammatory mediator, because its secretion is
mediated by inducers of inflammation (Medzhitov, 2008).
There is increasing evidence to suggest that IL-33 is a key
inflammatory mediator in a complex network of immune cells and
non-immune cells. When tissues receive insults which can lead to
inflammation, the major sources of IL-33 may be epithelial cells,
endothelial cells, or tissue macrophages (reviewed by Bartemes
and Kita, 2012). Research is coming closer to identifying the par-
ticular signals that rigger the secretion of IL-33 from the cells. The
production of IL-33 by epithelial cells has been reported in many
experimental models, including the following: (1) Upon exposure
to house dust mites, lung epithelial cells are activated by TLR4 to
release IL-1α and IL-1α in turn induces the release of IL-33 in an
autocrine fashion (Willart et al., 2012). (2) Similarly, lung epithe-
lial cells secrete IL-33 in response to the fungal allergen Alternaria
alternate through the induction of ATP release and its subsequent
activation of purinergic receptors (Kouzaki et al.,2012). (3) Finally,
intestinal epithelial cells release IL-33 in response to helminth
infection (Kang et al., 2012). It should be noted that epithelial cells
have various mechanism for amplifying inflammation in addition
to the initial recognition of danger cells or the production of early
endogenous DAMPs (Swamy et al., 2010; Kim et al., 2012b). Dis-
ruption of the epithelial cell barrier enables its cells to interact
with mesenchymal cells and immune cells, a process known to
contribute to the amplification loop of inflammation (Medzhitov,
2008; Kim et al., 2012b). A second source of tissue-cell IL-33 is the
macrophage. For example, RNA derived from the influenza virus
induces the secretion of IL-33 by alveolar macrophages through
TLR7 activation (Chang et al., 2011). Macrophages secrete IL-
33 following action by NKT cells and this in turn increases the
production of IL-13 by NKT cells and ILC2s (Kim et al., 2012a).
Finally, unidentified lung stromal cells were shown to release IL-
33 after stimulation of protease-activated receptors with protease
allergen papain (Halim et al., 2012).
IL-33 controls inflammation either positively or negatively; in
both cases the process is complex. A typical mechanism of IL-33
action on inflammation is to induce the production of additional
inflammatory mediators. An IL-33 target cell that has recently
received great attention is ILC2 which plays a critical role in Th2
inflammation by secreting IL-5 and IL-13 (Chang et al., 2011;
Bartemes et al., 2012; Kim et al., 2012a). IL-5 and IL-13 induce air-
way eosinophilia and hypersensitivity responses, respectively. As
ILC2s express a diverse array of cytokines and chemokines (Moro
et al., 2010; Neill et al., 2010; Monticelli et al., 2011), they may be
involved in a broad range of inflammatory processes, including
healing phases. For example, amphiregulin produced by ILC2s is
required for airway remodeling after infection with the influenza
virus (Monticelli et al., 2011). Skin fibrosis induced by IL-33 is
mediated by IL-13 (Rankin et al., 2010), suggesting that ILC2s
may be needed for chronic inflammation. Mast cells are another
type of cell involved in IL-33-induced inflammation. In the clinical
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FIGURE 3 | Examples of regulation of inflammation by IL-33. In
response to IL-33: (1) ILC2s regulate eosinophilia, hypersensitivity and skin
fibrosis, or tissue repair through IL-5, IL-13, or amphiregulin, respectively;
(2) dendritic cells (DCs) inhibit experimental autoimmune
encephalomyelitis (EAE); (3) hepatocytes are protected from
ischemia/reperfusion (I/R); (4) basophils secrete IL-4 which in turn
promotes the expression of the inhibitory FcγRIIB on effector
macrophages; and (5) mast cells produce IL-5, and IL-1β and IL-6 which are
involved in autoantibody production by autoreactive B cells and Th17
differentiation, respectively, in rheumatoid arthritis.
setting of rheumatoid arthritis, IL-33, secreted by synovial fibrob-
lasts, activates mast cells to produce proinflammatory cytokines
(Xu et al., 1998). Mast cells also secrete chemotactic factors for
neutrophil migration in response to IL-33 (Enoksson et al., 2012).
IL-33 suppresses inflammation in some clinical settings by
driving Th2 immunity. It does this by promoting either M2
macrophage (Kurowska-Stolarska et al., 2009; Hazlett et al., 2010)
or Th2 T-cell differentiation (Xu et al., 1998; Kurowska-Stolarska
et al., 2008; Groβ et al., 2012). However, the immunosuppressive
effects of IL-33 may also be due to its action on regulatory myeloid
cells. Dendritic cells are overactivated in the absence of ST2 signal-
ing in experimental autoimmune encephalomyelitis (Milovanovic
et al., 2012), suggesting that IL-33 has an immunoregulatory role
in these cells. In intravenous immunoglobulin (IVIG)-mediated
suppression of inflammation, IL-33 is a key component of the
autocrine loop of immunosuppression in regulatory macrophages
and dendritic cells (Anthony et al., 2011). The Fc of immunoglob-
ulin induces the production of IL-33 by macrophages through
CD209, and IL-33 in turn causes the expansion of IL-4-producing
basophils that promote the expression of the inhibitory Fc receptor
FcγRIIB on effector macrophages.
Recent studies have revealed IL-33 as a novel survival factor for
hepatocytes (Sakai et al., 2012). In vivo treatment of IL-33 has been
shown to decrease liver ischemia-reperfusion injury by preventing
necrosis of hepatocytes with no influence on production of proin-
flammatory mediators by Kupffer cells or hepatocytes (Sakai et al.,
2012).
It should be noted that IL-33 may be involved in the reso-
lution phase of inflammation. As mentioned above, amphireg-
ulin may be secreted by ILC2 in response to IL-33. In addi-
tion, ILC2s express cytokines involved in healing such as IL-
13 and TGF-β (Monticelli et al., 2011). Further studies will be
needed to define the involvement of IL-33 in the resolution
of inflammation. Figure 3 summarizes the roles of IL-33 in
inflammation.
CONCLUDING REMARKS
As a broad range of IL-33 targets have been identified, the
framework for IL-33 functionality has expanded beyond its well
documented role in Th2 immunity. In particular, IL-33 plays a
pivotal role in the link between injury at the mucosal barrier
and innate immunity. Injuries caused by extrinsic or intrinsic
factors result in the release or secretion of IL-33 from the epithe-
lial barrier. ILC2s and HSPCs paly an important role in IL-33-
mediated innate responses to injury, parasitic and viral infection,
and allergic inflammation. ILC2s and HSPCs produce a variety of
mediators involved in inflammatory and defense responses, cell
proliferation, and wound healing. Future studies will clarify the
elaborate mechanisms by which ILCs and HSPCS control local
inflammation.
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